

Supplemental Figure 1. Dose-Dependent Effect of CX-4945 on Cell Viability. (A-C) $CD4^+$ T cells were polarized to the Th1 **(A)**, Th17 **(B)** or Treg **(C)** phenotype in the presence of increasing concentrations of CX-4945. At 72 h, viability was measured by viability dye exclusion. **(D)** $CD4^+$ T cells were activated with plate-bound anti-CD3 (10 μg/ml) and soluble anti-CD28 (1 μg/ml) in the absence of additional cytokines and in the absence or presence of CX-4945 (2 μM). Viability measured by viability dye exclusion at indicated times.



Supplemental Figure 2. Effect of CX-4945 Treatment on Foxp3 Expression. (A) $CD4^+$ T cells were activated in the absence of cytokines (Th0) or polarized to the Th1 phenotype in the absence or presence of CX-4945 (2 μM) for 72 h, and Foxp3 expression was detected by flow cytometry. **(B)** $CD4^+$ T cells from *Il17f*$^{Thy1.1}$.*Foxp3*^{GFP} mice were polarized to the Th17 phenotype for 72 h. $Thy1.1^+$ cells were then sorted and then restimulated with no cytokine (NC), IL-12 (10 ng/ml), or TGFβ1 (5 ng/ml and IL-2 (5 ng/ml) for 24 h in the absence or presence of CX-4945 (2 μM). Foxp3 expression was detected by flow cytometry.



Supplemental Figure 3. Effect of *In Vivo* CX-4945 Treatment on Mouse Weight. C57BL/6 mice were treated with 20 mg/kg/day CX-4945 (n=5) or vehicle (n=4) from day 0 to 10, and weighed daily to detect potential toxicity.